There’s a version of European cannabis expansion that companies tend to imagine: translate the website, adapt the packaging, enter the market. Clean, linear, manageable.
Then there’s the reality.
In October 2025, Spain enacted its first-ever legal framework for medical cannabis — Real Decreto 903/2025, published in the BOE on 9 October, establishing a specific regulatory framework for the prescription, preparation, dispensing and use of standardised cannabis preparations for therapeutic purposes. Meanwhile, Germany had already restructured its entire medical cannabis architecture in April 2024, when the Cannabis Act (CanG) came into force, largely removing medical cannabis from the scope of the Narcotics Act and creating a dedicated Medical Cannabis Act (MedCanG).
Two European markets. Two regulatory overhauls within eighteen months of each other. And almost nothing in common in terms of how cannabis is framed, accessed, prescribed or communicated.
If you’re an anglophone cannabis company looking at Europe, this isn’t primarily a translation problem. It’s a regulatory linguistics problem. And the distinction matters more than most companies realise until they’ve already made a costly mistake.
Same Product. Different Institutional Logic.
The most important thing to understand about Germany and Spain is that they’ve reached similar destinations — regulated medical cannabis access — through completely different institutional routes. And those routes leave a fingerprint on every piece of communication you produce.
Germany built a pharmaceutical infrastructure. The MedCanG largely removed medical cannabis from the Narcotics Act and replaced the previous special narcotics prescription (the BtM-Rezept) with a standard prescription form. In principle, any licensed physician may now prescribe medical cannabis under the MedCanG framework, with dispensing handled through pharmacies across the country. The system is relatively decentralised and, until recently, compatible with telemedicine platforms — though proposed amendments to the MedCanG are moving to tighten those provisions.
Spain built a hospital system. Under RD 903/2025, formulas must be prepared exclusively by authorised hospital pharmacy services, and prescriptions are reserved for specialist physicians in the relevant pathologies, requiring documented clinical justification. At present, dispensing is limited to hospital pharmacy services, though the decree explicitly leaves open the possibility of future participation by community pharmacies in exceptional cases. The framework leaves little room for the kind of telemedicine-driven prescribing ecosystem that emerged in Germany. The access point is the hospital, and the gatekeeper is a specialist.
This structural difference isn’t just administrative context. It defines what language is appropriate, what claims are viable, what tone is credible, and what a patient or professional needs to hear.
The Language That Works in Berlin Won’t Work in Madrid
Here’s a concrete example of how this plays out.
In Germany, communications about medical cannabis increasingly circulate in a relatively accessible register. With the MedCanG removing the previous restriction to specific listed clinical indications, the prescription decision now depends primarily on the physician’s clinical judgement. This has contributed to a more conversational, patient-facing communication style in parts of the German cannabis market — one that addresses an informed audience navigating a relatively open prescribing environment.
In Spain, that tone would be a compliance problem and a credibility problem simultaneously. The model is, by design, highly medicalised and controlled: prescription is reserved to specialists, individualised clinical assessment is required, and access is generally contingent on documented failure of conventional treatments. Communications that suggest easy access, consumer choice or GP referral misrepresent the system entirely. The correct register is institutional, clinical and conservative — written for specialist physicians operating within a rigid public health framework, not for patients browsing their options.
Translate your German patient-facing content into Spanish, word for word, and you don’t just sound wrong. You sound non-compliant.
Terminology: Where the Differences Get Granular
Beyond tone, the actual terminology differs in ways that don’t resolve neatly with a dictionary.
“Fórmula magistral tipificada” has no direct German equivalent because the underlying concept operates differently in each system. These standardised preparations must be formulated in accordance with the AEMPS monograph and prepared under the supervision of a hospital pharmacist according to the applicable Good Manufacturing Practices. This is a specific Spanish legal construct — a compounded preparation that has been standardised and registered nationally with the AEMPS. Translating it into German requires navigating a different pharmaceutical dispensing logic, not simply finding a matching term, because the institutional role that concept fills in the Spanish system doesn’t map directly onto German pharmaceutical practice.
“Preparados estandarizados de cannabis” in Spanish communicates AEMPS oversight, hospital pharmacy production and national registration. Under the MedCanG, medicinal cannabis is defined as plants, flowers and other parts of plants belonging to the genus cannabis originating from cultivation for medical purposes under state control. Same product category, different definitional logic, different regulatory anchors.
THC thresholds are stated differently in each jurisdiction. Under RD 903/2025, preparations containing THC at or above 0.2% by weight are considered psychotropic and subject to additional control measures under the 1971 Convention on Psychotropic Substances. German communications around the same threshold reference different legislative frameworks — the MedCanG and its relationship to the now-reformed BtMG — and speak to different enforcement bodies. Using the Spanish framing in a German document, or vice versa, isn’t wrong in the way a typo is wrong. It signals that the author doesn’t actually understand the system they’re writing about.
The Compliance Gap Is a Communication Gap
Most cannabis companies entering Europe treat regulatory compliance as a legal checkbox: engage a local lawyer, review the claims, remove anything flagged. That approach is necessary but not sufficient.
What it doesn’t address is the underlying communication architecture — the institutional assumptions embedded in how you structure information, who you address it to, what you assume your reader already knows, and what level of clinical authority you invoke.
A German patient information document assumes the reader may have initiated the consultation themselves and is navigating a relatively open prescribing environment. A Spanish clinical communication assumes a specialist physician operating within a strictly controlled hospital protocol, prescribing for a patient who has exhausted conventional treatments.
These aren’t just different markets. They’re different relationships between the cannabis product and the institution that controls access to it. Getting that relationship wrong in writing — even if every individual claim is technically accurate — produces content that doesn’t land, doesn’t convert and doesn’t build trust.
What This Means in Practice
If you’re preparing to communicate about medical cannabis in Germany and Spain, the starting question isn’t “how do we translate this?” It’s more fundamental than that.
Who is actually reading this? In Germany, it might be a patient who found out last week that their GP can now prescribe cannabis without a special form, or a specialist who’s been doing it for years. In Spain, in the current regulatory model, you’re almost certainly writing for a hospital specialist who operates inside a documented clinical protocol and has no interest in language that suggests the patient chose to be there.
That single answer changes everything: structure, register, the claims you make, the authority you invoke.
The institutional frame matters too. German physicians now work under a non-narcotic prescription framework — cannabis is no longer classified the way it previously was, and standard prescriptions apply. Spanish specialists operate within a public health system that is, by design, conservative and evidence-based. The language that reads as credible differs not just in degree but in kind.
And then there’s the legal scaffolding. Citing “compliance with MedCanG” in a Spanish document — or “compliance with RD 903/2025” in a German one — isn’t just a localisation error. It tells the reader you didn’t read either law. In a regulated industry, that’s not a small thing.
Finally, advertising. Restrictions for prescription medicinal products remain tightly regulated in both markets: in Germany under the Heilmittelwerbegesetz (HWG); in Spain under the Ley de Garantías y Uso Racional de los Medicamentos y Productos Sanitarios. These frameworks aren’t interchangeable, and content built for one jurisdiction won’t automatically satisfy the other.
The Case for Regulatory Linguistics
The wine industry figured this out decades ago. A producer entering the German market didn’t just translate the label. They understood that Qualitätswein, Prädikatswein and the Prüfungsnummer system were regulatory concepts that carried specific meaning for German buyers — and that getting them wrong was a signal of amateur execution, regardless of how good the wine was.
Cannabis is at the same inflection point, except the stakes are higher because the regulatory environment is younger, faster-moving and more consequential for patients.
What European cannabis expansion actually requires is not translation in the conventional sense. It’s the ability to read a regulatory framework and reconstruct the communication layer that belongs to it — tone, terminology, institutional address, claims architecture and all.
That’s what we mean by regulatory linguistics at Cannaspeaks. And it’s the difference between content that opens doors in a new market and content that quietly closes them.
If you’re preparing communications for the German or Spanish medical cannabis markets, we’d be glad to talk. Contact us here.
Sources
- Real Decreto 903/2025, de 7 de octubre. BOE núm. 243, 9 de octubre de 2025. boe.es
- DLA Piper: “España regula por primera vez el uso medicinal del cannabis.” October 2025.
- Gleiss Lutz: “Update on cannabis legalisation: German Federal Government to prohibit telemedical prescriptions of medical cannabis.” December 2025.
- Chambers & Partners: “Medical Cannabis & Cannabinoid Regulation 2025 — Germany.”
- SKW Schwarz: “The Medical Cannabis Act at a Glance: Legalization with conditions.” 2024.
- Cuatrecasas: “Cannabis medicinal en España.” October 2025.
- ECA Academy: “German Draft Act to amend Cannabis Prescription.” July 2025.
Rocío del Amo is the founder of Cannaspeaks, a boutique linguistic consultancy specialising exclusively in the cannabis sector. With 10+ years of experience in specialised translation — first in wine, now in cannabis — she works with international cannabis companies navigating European regulatory and linguistic complexity. About Rocío
Comentarios recientes